TWiV 1132: Clinical update with Dr. Daniel Griffin
This Week in Virology
Intro
Dr. Daniel Griffin talks about President Biden testing positive for COVID-19 and beginning treatment with Paxlovid, highlighting the risks, importance of ongoing care, and long-term effects on older individuals.
In his weekly clinical update, Dr, Daniel Griffin reviews President Biden’s case of COVID, reviews recent statistics on SARS-CoV-2 infection, discusses post-acute sequelae after infection during pregnancy, the use of nirmatrelvir-ritonavir for post-exposure prophylaxis, where to find Pemgarda, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment, effectiveness of Ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment in patients hospitalized with COVID-19, CDC update of Long COVID Basics page, postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras, Long COVID risk has dropped over time but remains substantial, efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID, and the interplay between diet and the gut microbiome: implications for health and disease.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- President Biden has COVID (CNN, USA Today)
- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Post–acute sequelae of COVID after infection during pregnancy (OB & Gyn)
- Oral nirmatrelvir–ritonavir as postexposure prophylaxis for Covid-19 (NEJM)
- Pemgarda infusion center locator (Pemgarda)
- Unable to access pemgarda, gotta call Daniel (microbeTV)
- CDC Quarantine guidelines (CDC)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Combined treatment of COVID reduces molnupiravir-induced mutagenicity (J Inf Dis)
- Effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19 (Inf Dis Therapy)
- Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy (Lancet)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- Isolation guidance (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Long COVID is defined (National Academies)
- Long COVID: the ANSWERS! (longcovidtheanswers.com)
- The FACTS: post COVID-19=long COVID? (WHO)
- The BASICS of long COVID-19 (CDC)
- Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras (NEJM)
- Long Covid risk has dropped over time but remains substantial (CNN)
- Efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID (Clin Micro Inf)
- Diet and the gut microbiome: implications for health and disease (Nat Rev Micro)
- Contribute to our Floating Doctors fundraiser
- Letters read on TWiV 1132
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The AI-powered Podcast Player
